Coherus Oncology (CHRS) Gross Profit (2019 - 2026)

Coherus Oncology has disclosed Gross Profit across 8 years of filings, most recently posting $8.5 million for Q1 2026.

• Gross Profit for Q1 2026 came in at $8.5 million, up 71.78% year-over-year; the trailing twelve-month figure through Mar 2026 was $31.9 million (up 46.78% YoY), and the FY2025 annual result was $28.4 million, up 60.56% from the prior year.
• Gross Profit came in at $8.5 million for Q1 2026 at Coherus Oncology, down from $8.7 million in the prior quarter.
• In the past five years, Gross Profit ranged from a high of $50.7 million in Q1 2022 to a low of $869000.0 in Q1 2024.
• The 5-year median for Gross Profit is $8.5 million (2026), against an average of $17.3 million.
• Across the five-year window, Gross Profit plunged 94.42% in 2024 and soared 469.16% in 2025, its largest moves.
• Coherus Oncology's Gross Profit stood at $31.2 million in 2022, then sank by 77.67% to $7.0 million in 2023, then decreased by 28.37% to $5.0 million in 2024, then jumped by 74.65% to $8.7 million in 2025, then declined by 2.38% to $8.5 million in 2026.
• The last three Gross Profit figures came in at $8.5 million (Q1 2026), $8.7 million (Q4 2025), and $7.8 million (Q3 2025), per Business Quant data.